Imjudo

Imjudo (tremelimumab) is given as an infusion through the vein (IV). It’s uncommon, but some people have reactions to the IV infusion. You’ll be monitored for an hour after finishing your Imjudo (tremelimumab) infusion to make sure you don’t have any reactions to the treatment. Let your healthcare team know immediately if you notice any signs of an infusion reaction, like trouble breathing, dizziness, chest pain, flushing, or chills during or after the infusion. They can pause the infusion and manage your symptoms. Once the reaction is under control, they can restart the infusion at a slower rate, and give you medications to prevent reactions in the future.

It’s common to have rash with Imjudo (tremelimumab) that can be itchy. Let your healthcare team know if you have a worsening rash, blisters, or peeling skin. They might recommend other treatments for your rash and have you take a break from Imjudo (tremelimumab) while your skin returns to normal.

Fatigue is a common side effect of cancer treatments including Imjudo (tremelimumab). If you feel tired or weak, do your best to stay well-rested, eat well, and stay hydrated. Light exercise and movement can also help prevent fatigue. You might need to adjust your routine to schedule activities when you have more energy.

Diarrhea is another common Imjudo (tremelimumab) side effect. Keep track of your bowel habits to make sure you’re having regular bowel movements while taking this medication. Contact your healthcare team if you notice blood or mucus in your stool, have severe stomach pain, or are having more bowel movements a day than usual. They’ll check if you have an infection that’s causing your diarrhea, make sure the diarrhea isn’t making you dehydrated, and recommend strategies or medications to manage the diarrhea.

Immune-related adverse events are rare but serious side effects of immunotherapy, including Imjudo (tremelimumab). These side effects can happen to any part of your body at any time, even after you’ve stopped taking this medication. Your provider will monitor your blood tests to check if you have signs of these reactions. Keep track of how you’re feeling, and contact your provider if you notice anything out of the ordinary with your body, such as new or worsening shortness of breath, skin changes, chest pain, vision changes, or muscle and joint soreness.

Imjudo (tremelimumab) is likely to cause harm or death to the unborn baby, based on studies done in animals. If you’re able to become pregnant, your provider will have you do a pregnancy test before starting this medication. Use birth control while on Imjudo (tremelimumab) and for 3 months after stopping this medication.

There aren’t any studies about whether Imjudo (tremelimumab) is safe while breastfeeding, so you should avoid breastfeeding while taking Imjudo (tremelimumab) and for at least 3 months after stopping the medication.